We read with great interest the article by Stepanova et al. 1 In this report from the United States with 10,582 eligible individuals (1.52% of whom were positive for hepatitis C virus [HCV] antibody [anti-HCV]), the rate of insurance coverage was significantly lower in patients with HCV infection (6
Human cytomegalovirus infection inhibits response of chronic hepatitis-C-virus-infected patients to interferon-based therapy
โ Scribed by Noha G Bader El Din; Mai Abd El Meguid; Ashraf A Tabll; Mohamed A Anany; Gamal Esmat; Naglaa Zayed; Amr Helmy; Abdel Rahman El Zayady; Ahmed Barakat; Mostafa K El Awady
- Book ID
- 108953743
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 196 KB
- Volume
- 26
- Category
- Article
- ISSN
- 0815-9319
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
To determine the patient-dependent and virusrelated factors that may predict sustained response to interferon-a therapy, we prospectively evaluated 60 consecutive patients with chronic hepatitis C who received a standardized treatment schedule of interferon-a. Twenty-eight patients achieved a long-t
## Abstract The use of quantitative assays for hepatitis C virus specific antibodies (antiโHCV) as a prognostic marker was evaluated in 31 patients with chronic hepatitis C treated with interferon (IFN). Changes in titers of serum HCVโRNA and antiโHCV antibodies; antiโC11 (antiโcore), antiโC100 (an